Medical Care
Global Next-Generation Breast Cancer Diagnostic and Screening Market Research Report 2025
- Jul 08, 25
- ID: 348638
- Pages: 81
- Figures: 87
- Views: 12
The global market for Next-Generation Breast Cancer Diagnostic and Screening was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Next-Generation Breast Cancer Diagnostic and Screening, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Breast Cancer Diagnostic and Screening.
The Next-Generation Breast Cancer Diagnostic and Screening market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Next-Generation Breast Cancer Diagnostic and Screening market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next-Generation Breast Cancer Diagnostic and Screening companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Agendia
Agilent Technologies
Ambry Genetics
Biocept
Biotheranostics
Centogene
Danaher Corporation
EXACT Sciences Corporation
Roche Holding AG
Fulgent Genetics
Illumina
Invitae
Lucence Diagnostics Pte Ltd
Myriad Genetics
Segment by Type
Real-Time PCR (q-PCR)
Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Fluorescent In-Situ Hybridization (FISH)
Segment by Application
Hospital-associated Labs
Cancer Research Institutes
Diagnostic Centers
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next-Generation Breast Cancer Diagnostic and Screening company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Next-Generation Breast Cancer Diagnostic and Screening, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Breast Cancer Diagnostic and Screening.
The Next-Generation Breast Cancer Diagnostic and Screening market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Next-Generation Breast Cancer Diagnostic and Screening market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next-Generation Breast Cancer Diagnostic and Screening companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Agendia
Agilent Technologies
Ambry Genetics
Biocept
Biotheranostics
Centogene
Danaher Corporation
EXACT Sciences Corporation
Roche Holding AG
Fulgent Genetics
Illumina
Invitae
Lucence Diagnostics Pte Ltd
Myriad Genetics
Segment by Type
Real-Time PCR (q-PCR)
Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Fluorescent In-Situ Hybridization (FISH)
Segment by Application
Hospital-associated Labs
Cancer Research Institutes
Diagnostic Centers
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next-Generation Breast Cancer Diagnostic and Screening company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Real-Time PCR (q-PCR)
1.2.3 Immunohistochemistry (IHC)
1.2.4 Next-Generation Sequencing (NGS)
1.2.5 Fluorescent In-Situ Hybridization (FISH)
1.3 Market by Application
1.3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital-associated Labs
1.3.3 Cancer Research Institutes
1.3.4 Diagnostic Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Perspective (2020-2031)
2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Growth Trends by Region
2.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Region (2020-2025)
2.2.3 Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2026-2031)
2.3 Next-Generation Breast Cancer Diagnostic and Screening Market Dynamics
2.3.1 Next-Generation Breast Cancer Diagnostic and Screening Industry Trends
2.3.2 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
2.3.3 Next-Generation Breast Cancer Diagnostic and Screening Market Challenges
2.3.4 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue
3.1.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue (2020-2025)
3.1.2 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Players (2020-2025)
3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Next-Generation Breast Cancer Diagnostic and Screening Revenue
3.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio
3.4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2024
3.5 Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening Head office and Area Served
3.6 Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Product and Application
3.7 Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Type
4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Type (2020-2025)
4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2026-2031)
5 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Application
5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Application (2020-2025)
5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)
6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)
6.4 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)
7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)
7.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)
8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2020-2025)
8.4 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)
9.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)
9.4 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)
10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)
10.4 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.1.4 Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.1.5 Abbott Laboratories Recent Development
11.2 Agendia
11.2.1 Agendia Company Details
11.2.2 Agendia Business Overview
11.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.2.4 Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.2.5 Agendia Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Details
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.3.4 Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.3.5 Agilent Technologies Recent Development
11.4 Ambry Genetics
11.4.1 Ambry Genetics Company Details
11.4.2 Ambry Genetics Business Overview
11.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.4.4 Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.4.5 Ambry Genetics Recent Development
11.5 Biocept
11.5.1 Biocept Company Details
11.5.2 Biocept Business Overview
11.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.5.4 Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.5.5 Biocept Recent Development
11.6 Biotheranostics
11.6.1 Biotheranostics Company Details
11.6.2 Biotheranostics Business Overview
11.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.6.4 Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.6.5 Biotheranostics Recent Development
11.7 Centogene
11.7.1 Centogene Company Details
11.7.2 Centogene Business Overview
11.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.7.4 Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.7.5 Centogene Recent Development
11.8 Danaher Corporation
11.8.1 Danaher Corporation Company Details
11.8.2 Danaher Corporation Business Overview
11.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.8.4 Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.8.5 Danaher Corporation Recent Development
11.9 EXACT Sciences Corporation
11.9.1 EXACT Sciences Corporation Company Details
11.9.2 EXACT Sciences Corporation Business Overview
11.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.9.4 EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.9.5 EXACT Sciences Corporation Recent Development
11.10 Roche Holding AG
11.10.1 Roche Holding AG Company Details
11.10.2 Roche Holding AG Business Overview
11.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.10.4 Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.10.5 Roche Holding AG Recent Development
11.11 Fulgent Genetics
11.11.1 Fulgent Genetics Company Details
11.11.2 Fulgent Genetics Business Overview
11.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.11.4 Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.11.5 Fulgent Genetics Recent Development
11.12 Illumina
11.12.1 Illumina Company Details
11.12.2 Illumina Business Overview
11.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.12.4 Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.12.5 Illumina Recent Development
11.13 Invitae
11.13.1 Invitae Company Details
11.13.2 Invitae Business Overview
11.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.13.4 Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.13.5 Invitae Recent Development
11.14 Lucence Diagnostics Pte Ltd
11.14.1 Lucence Diagnostics Pte Ltd Company Details
11.14.2 Lucence Diagnostics Pte Ltd Business Overview
11.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.14.4 Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.14.5 Lucence Diagnostics Pte Ltd Recent Development
11.15 Myriad Genetics
11.15.1 Myriad Genetics Company Details
11.15.2 Myriad Genetics Business Overview
11.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.15.4 Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.15.5 Myriad Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Real-Time PCR (q-PCR)
1.2.3 Immunohistochemistry (IHC)
1.2.4 Next-Generation Sequencing (NGS)
1.2.5 Fluorescent In-Situ Hybridization (FISH)
1.3 Market by Application
1.3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital-associated Labs
1.3.3 Cancer Research Institutes
1.3.4 Diagnostic Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Perspective (2020-2031)
2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Growth Trends by Region
2.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Region (2020-2025)
2.2.3 Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2026-2031)
2.3 Next-Generation Breast Cancer Diagnostic and Screening Market Dynamics
2.3.1 Next-Generation Breast Cancer Diagnostic and Screening Industry Trends
2.3.2 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
2.3.3 Next-Generation Breast Cancer Diagnostic and Screening Market Challenges
2.3.4 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue
3.1.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue (2020-2025)
3.1.2 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Players (2020-2025)
3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Next-Generation Breast Cancer Diagnostic and Screening Revenue
3.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio
3.4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2024
3.5 Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening Head office and Area Served
3.6 Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Product and Application
3.7 Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Type
4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Type (2020-2025)
4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2026-2031)
5 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Application
5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Application (2020-2025)
5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)
6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)
6.4 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)
7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)
7.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)
8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2020-2025)
8.4 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)
9.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)
9.4 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size (2020-2031)
10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025)
10.4 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.1.4 Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.1.5 Abbott Laboratories Recent Development
11.2 Agendia
11.2.1 Agendia Company Details
11.2.2 Agendia Business Overview
11.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.2.4 Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.2.5 Agendia Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Details
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.3.4 Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.3.5 Agilent Technologies Recent Development
11.4 Ambry Genetics
11.4.1 Ambry Genetics Company Details
11.4.2 Ambry Genetics Business Overview
11.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.4.4 Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.4.5 Ambry Genetics Recent Development
11.5 Biocept
11.5.1 Biocept Company Details
11.5.2 Biocept Business Overview
11.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.5.4 Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.5.5 Biocept Recent Development
11.6 Biotheranostics
11.6.1 Biotheranostics Company Details
11.6.2 Biotheranostics Business Overview
11.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.6.4 Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.6.5 Biotheranostics Recent Development
11.7 Centogene
11.7.1 Centogene Company Details
11.7.2 Centogene Business Overview
11.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.7.4 Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.7.5 Centogene Recent Development
11.8 Danaher Corporation
11.8.1 Danaher Corporation Company Details
11.8.2 Danaher Corporation Business Overview
11.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.8.4 Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.8.5 Danaher Corporation Recent Development
11.9 EXACT Sciences Corporation
11.9.1 EXACT Sciences Corporation Company Details
11.9.2 EXACT Sciences Corporation Business Overview
11.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.9.4 EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.9.5 EXACT Sciences Corporation Recent Development
11.10 Roche Holding AG
11.10.1 Roche Holding AG Company Details
11.10.2 Roche Holding AG Business Overview
11.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.10.4 Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.10.5 Roche Holding AG Recent Development
11.11 Fulgent Genetics
11.11.1 Fulgent Genetics Company Details
11.11.2 Fulgent Genetics Business Overview
11.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.11.4 Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.11.5 Fulgent Genetics Recent Development
11.12 Illumina
11.12.1 Illumina Company Details
11.12.2 Illumina Business Overview
11.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.12.4 Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.12.5 Illumina Recent Development
11.13 Invitae
11.13.1 Invitae Company Details
11.13.2 Invitae Business Overview
11.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.13.4 Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.13.5 Invitae Recent Development
11.14 Lucence Diagnostics Pte Ltd
11.14.1 Lucence Diagnostics Pte Ltd Company Details
11.14.2 Lucence Diagnostics Pte Ltd Business Overview
11.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.14.4 Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.14.5 Lucence Diagnostics Pte Ltd Recent Development
11.15 Myriad Genetics
11.15.1 Myriad Genetics Company Details
11.15.2 Myriad Genetics Business Overview
11.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.15.4 Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
11.15.5 Myriad Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Real-Time PCR (q-PCR)
Table 3. Key Players of Immunohistochemistry (IHC)
Table 4. Key Players of Next-Generation Sequencing (NGS)
Table 5. Key Players of Fluorescent In-Situ Hybridization (FISH)
Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2020-2025)
Table 10. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2026-2031)
Table 12. Next-Generation Breast Cancer Diagnostic and Screening Market Trends
Table 13. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
Table 14. Next-Generation Breast Cancer Diagnostic and Screening Market Challenges
Table 15. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
Table 16. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players (2020-2025)
Table 18. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2024)
Table 19. Ranking of Global Top Next-Generation Breast Cancer Diagnostic and Screening Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Headquarters and Area Served
Table 22. Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Product and Application
Table 23. Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2020-2025)
Table 27. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2026-2031)
Table 29. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2020-2025)
Table 31. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2026-2031)
Table 33. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)
Table 48. Abbott Laboratories Company Details
Table 49. Abbott Laboratories Business Overview
Table 50. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product
Table 51. Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 52. Abbott Laboratories Recent Development
Table 53. Agendia Company Details
Table 54. Agendia Business Overview
Table 55. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product
Table 56. Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 57. Agendia Recent Development
Table 58. Agilent Technologies Company Details
Table 59. Agilent Technologies Business Overview
Table 60. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product
Table 61. Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 62. Agilent Technologies Recent Development
Table 63. Ambry Genetics Company Details
Table 64. Ambry Genetics Business Overview
Table 65. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 66. Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 67. Ambry Genetics Recent Development
Table 68. Biocept Company Details
Table 69. Biocept Business Overview
Table 70. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product
Table 71. Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 72. Biocept Recent Development
Table 73. Biotheranostics Company Details
Table 74. Biotheranostics Business Overview
Table 75. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 76. Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 77. Biotheranostics Recent Development
Table 78. Centogene Company Details
Table 79. Centogene Business Overview
Table 80. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product
Table 81. Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 82. Centogene Recent Development
Table 83. Danaher Corporation Company Details
Table 84. Danaher Corporation Business Overview
Table 85. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product
Table 86. Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 87. Danaher Corporation Recent Development
Table 88. EXACT Sciences Corporation Company Details
Table 89. EXACT Sciences Corporation Business Overview
Table 90. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product
Table 91. EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 92. EXACT Sciences Corporation Recent Development
Table 93. Roche Holding AG Company Details
Table 94. Roche Holding AG Business Overview
Table 95. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product
Table 96. Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 97. Roche Holding AG Recent Development
Table 98. Fulgent Genetics Company Details
Table 99. Fulgent Genetics Business Overview
Table 100. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 101. Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 102. Fulgent Genetics Recent Development
Table 103. Illumina Company Details
Table 104. Illumina Business Overview
Table 105. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product
Table 106. Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 107. Illumina Recent Development
Table 108. Invitae Company Details
Table 109. Invitae Business Overview
Table 110. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product
Table 111. Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 112. Invitae Recent Development
Table 113. Lucence Diagnostics Pte Ltd Company Details
Table 114. Lucence Diagnostics Pte Ltd Business Overview
Table 115. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product
Table 116. Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 117. Lucence Diagnostics Pte Ltd Recent Development
Table 118. Myriad Genetics Company Details
Table 119. Myriad Genetics Business Overview
Table 120. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 121. Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 122. Myriad Genetics Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Next-Generation Breast Cancer Diagnostic and Screening Picture
Figure 2. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type: 2024 VS 2031
Figure 4. Real-Time PCR (q-PCR) Features
Figure 5. Immunohistochemistry (IHC) Features
Figure 6. Next-Generation Sequencing (NGS) Features
Figure 7. Fluorescent In-Situ Hybridization (FISH) Features
Figure 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application: 2024 VS 2031
Figure 10. Hospital-associated Labs Case Studies
Figure 11. Cancer Research Institutes Case Studies
Figure 12. Diagnostic Centers Case Studies
Figure 13. Next-Generation Breast Cancer Diagnostic and Screening Report Years Considered
Figure 14. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region: 2024 VS 2031
Figure 17. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players in 2024
Figure 18. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2024
Figure 20. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)
Figure 22. United States Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)
Figure 26. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2020-2031)
Figure 34. China Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)
Figure 42. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)
Figure 46. Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Abbott Laboratories Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 50. Agendia Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 51. Agilent Technologies Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 52. Ambry Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 53. Biocept Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 54. Biotheranostics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 55. Centogene Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 56. Danaher Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 57. EXACT Sciences Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 58. Roche Holding AG Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 59. Fulgent Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 60. Illumina Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 61. Invitae Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 62. Lucence Diagnostics Pte Ltd Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 63. Myriad Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Table 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Real-Time PCR (q-PCR)
Table 3. Key Players of Immunohistochemistry (IHC)
Table 4. Key Players of Next-Generation Sequencing (NGS)
Table 5. Key Players of Fluorescent In-Situ Hybridization (FISH)
Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2020-2025)
Table 10. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2026-2031)
Table 12. Next-Generation Breast Cancer Diagnostic and Screening Market Trends
Table 13. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
Table 14. Next-Generation Breast Cancer Diagnostic and Screening Market Challenges
Table 15. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
Table 16. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players (2020-2025)
Table 18. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2024)
Table 19. Ranking of Global Top Next-Generation Breast Cancer Diagnostic and Screening Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Headquarters and Area Served
Table 22. Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Product and Application
Table 23. Global Key Players of Next-Generation Breast Cancer Diagnostic and Screening, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2020-2025)
Table 27. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2026-2031)
Table 29. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2020-2025)
Table 31. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2026-2031)
Table 33. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2026-2031) & (US$ Million)
Table 48. Abbott Laboratories Company Details
Table 49. Abbott Laboratories Business Overview
Table 50. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product
Table 51. Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 52. Abbott Laboratories Recent Development
Table 53. Agendia Company Details
Table 54. Agendia Business Overview
Table 55. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product
Table 56. Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 57. Agendia Recent Development
Table 58. Agilent Technologies Company Details
Table 59. Agilent Technologies Business Overview
Table 60. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product
Table 61. Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 62. Agilent Technologies Recent Development
Table 63. Ambry Genetics Company Details
Table 64. Ambry Genetics Business Overview
Table 65. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 66. Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 67. Ambry Genetics Recent Development
Table 68. Biocept Company Details
Table 69. Biocept Business Overview
Table 70. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product
Table 71. Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 72. Biocept Recent Development
Table 73. Biotheranostics Company Details
Table 74. Biotheranostics Business Overview
Table 75. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 76. Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 77. Biotheranostics Recent Development
Table 78. Centogene Company Details
Table 79. Centogene Business Overview
Table 80. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product
Table 81. Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 82. Centogene Recent Development
Table 83. Danaher Corporation Company Details
Table 84. Danaher Corporation Business Overview
Table 85. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product
Table 86. Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 87. Danaher Corporation Recent Development
Table 88. EXACT Sciences Corporation Company Details
Table 89. EXACT Sciences Corporation Business Overview
Table 90. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product
Table 91. EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 92. EXACT Sciences Corporation Recent Development
Table 93. Roche Holding AG Company Details
Table 94. Roche Holding AG Business Overview
Table 95. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product
Table 96. Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 97. Roche Holding AG Recent Development
Table 98. Fulgent Genetics Company Details
Table 99. Fulgent Genetics Business Overview
Table 100. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 101. Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 102. Fulgent Genetics Recent Development
Table 103. Illumina Company Details
Table 104. Illumina Business Overview
Table 105. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product
Table 106. Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 107. Illumina Recent Development
Table 108. Invitae Company Details
Table 109. Invitae Business Overview
Table 110. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product
Table 111. Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 112. Invitae Recent Development
Table 113. Lucence Diagnostics Pte Ltd Company Details
Table 114. Lucence Diagnostics Pte Ltd Business Overview
Table 115. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product
Table 116. Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 117. Lucence Diagnostics Pte Ltd Recent Development
Table 118. Myriad Genetics Company Details
Table 119. Myriad Genetics Business Overview
Table 120. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 121. Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025) & (US$ Million)
Table 122. Myriad Genetics Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Next-Generation Breast Cancer Diagnostic and Screening Picture
Figure 2. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type: 2024 VS 2031
Figure 4. Real-Time PCR (q-PCR) Features
Figure 5. Immunohistochemistry (IHC) Features
Figure 6. Next-Generation Sequencing (NGS) Features
Figure 7. Fluorescent In-Situ Hybridization (FISH) Features
Figure 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application: 2024 VS 2031
Figure 10. Hospital-associated Labs Case Studies
Figure 11. Cancer Research Institutes Case Studies
Figure 12. Diagnostic Centers Case Studies
Figure 13. Next-Generation Breast Cancer Diagnostic and Screening Report Years Considered
Figure 14. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region: 2024 VS 2031
Figure 17. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players in 2024
Figure 18. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2024
Figure 20. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)
Figure 22. United States Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)
Figure 26. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2020-2031)
Figure 34. China Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)
Figure 42. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2020-2031)
Figure 46. Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Abbott Laboratories Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 50. Agendia Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 51. Agilent Technologies Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 52. Ambry Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 53. Biocept Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 54. Biotheranostics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 55. Centogene Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 56. Danaher Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 57. EXACT Sciences Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 58. Roche Holding AG Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 59. Fulgent Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 60. Illumina Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 61. Invitae Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 62. Lucence Diagnostics Pte Ltd Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 63. Myriad Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global White Oil Market Research Report 2025
Aug 11, 25
Global Piezo Materials Market Research Report 2025
Aug 11, 25
Global Piezoceramic Materials Market Research Report 2025
Aug 11, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232